19 September 2022: Clinical Research
Circulating Methylated DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
Zhen Yuan 12ABCEF* , Shuyuan Wang 12ABCDEF* , Kemin Ni 12ACDF* , Yixiang Zhan 12ACDF* , Hong Ma 1BDF , Xinyu Liu 13ABC , Ran Xin 2ABC , Xingyu Zhou 2BC , Zhaoce Liu 12BC , Xuanzhu Zhao 14BC , Xin Yin 2BC , Hangyu Ping 2BC , Yaohong Liu 2BC , Wanting Wang 4BC , Suying Yan 4BC , Qiurong Han 4BC , Wei Cui 5CD , Xipeng Zhang 167ADF , Qinghuai Zhang 167ABCD* , Chunze Zhang 167ABCDEFG*DOI: 10.12659/MSM.937757
Med Sci Monit 2022; 28:e937757
Table 1 Baseline characteristics of patients with stage II–III colorectal cancer.
| Total number (n=426) | Preoperative mSEPT9 (n=348) | Postoperative mSEPT9 (n=339) | Longitudinal mSETP9 (n=426) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive (n=173) | Negative (n=175) | p value | Positive (n=60) | Negative (n=279) | p value | Positive (n=110) | Negative (n=316) | p value | ||
| ≤60 years | 186 (43.7) | 79 (45.7) | 78 (44.6) | 0.914 | 21 (35) | 127 (45.5) | 0.153 | 36 (32.7) | 150 (47.5) | 0.008 |
| >60 years | 240 (56.3) | 94 (54.3) | 97 (55.4) | 39 (65) | 152 (54.5) | 74 (67.3) | 166 (52.5) | |||
| Female | 173 (40.6) | 72 (41.6) | 71 (40.6) | 0.913 | 25 (41.7) | 115 (41.2) | 1.000 | 39 (35.5) | 134 (42.4) | 0.216 |
| Male | 253 (59.4) | 101 (58.4) | 104 (59.4) | 35 (58.3) | 164 (58.8) | 71 (64.5) | 182 (57.6) | |||
| Well/moderate | 277 (65.0) | 113 (65.3) | 110 (62.9) | 0.656 | 31 (51.7) | 183 (65.6) | 0.055 | 62 (56.4) | 215 (68) | 0.036 |
| Poor | 149 (35.0) | 60 (34.7) | 65 (37.1) | 29 (48.3) | 96 (34.4) | 48 (43.6) | 101 (32) | |||
| Adenocarcinoma | 393 (92.3) | 164 (94.8) | 154 (88) | 0.034 | 53 (88.3) | 256 (91.8) | 0.450 | 100 (90.9) | 293 (92.7) | 0.538 |
| Other types | 33 (7.7) | 9 (5.2) | 21 (12) | 7 (11.7) | 23 (8.2) | 10 (9.1) | 23 (7.3) | |||
| II | 180 (42.3) | 78 (45.1) | 74 (42.3) | 0.666 | 18 (30.0) | 122 (43.7) | 0.060 | 36 (32.7) | 144 (45.6) | 0.019 |
| III | 246 (57.7) | 95 (54.9) | 101 (57.7) | 42 (70.0) | 157 (56.3) | 74 (67.3) | 172 (54.4) | |||
| pT1 | 1 (0.2) | 0 (0.0) | 1 (0.6) | 0.190 | 0 (0.0) | 1 (0.4) | 0.899 | 0 (0.0) | 1 (0.3) | 0.400 |
| pT2 | 19 (4.5) | 3 (1.7) | 15 (8.6) | 3 (5.0) | 12 (4.3) | 5 (4.5) | 14 (4.4) | |||
| pT3 | 262 (61.5) | 111 (64.2) | 103 (58.9) | 37 (61.7) | 171 (61.3) | 64 (58.2) | 198 (62.7) | |||
| pT4 | 144 (33.8) | 59 (34.1) | 56 (32.0) | 20 (33.3) | 95 (34.1) | 41 (37.3) | 103 (32.6) | |||
| pN0 | 180 (42.3) | 78 (45.1) | 74 (42.3) | 0.398 | 18 (30.0) | 122 (43.7) | 0.031 | 36 (32.7) | 144 (45.6) | 0.030 |
| pN1 | 176 (41.3) | 71 (41) | 69 (39.4) | 28 (46.7) | 115 (41.2) | 53 (48.2) | 123 (38.9) | |||
| pN2 | 70 (16.4) | 24 (13.9) | 32 (18.3) | 14 (23.3) | 42 (15.1) | 21 (19.1) | 49 (15.5) | |||
| Rectum | 227 (53.3) | 86 (49.7) | 94 (53.7) | 0.524 | 31 (51.7) | 138 (49.5) | 0.718 | 56 (50.9) | 171 (54.1) | 0.781 |
| Left colon | 115 (27.0) | 54 (31.2) | 45 (25.7) | 14 (23.3) | 79 (28.3) | 30 (27.3) | 85 (26.9) | |||
| Right colon | 84 (19.7) | 33 (19.1) | 36 (20.6) | 15 (25.0) | 62 (22.2) | 24 (21.8) | 60 (19.0) | |||
| No ACT | 26 (6.1) | 13 (7.5) | 10 (5.7) | 0.653 | 4 (6.7) | 11 (3.9) | 1.000 | 6 (5.5) | 20 (6.3) | 0.220 |
| ACT | 400 (93.9) | 160 (92.5) | 165 (94.3) | 56 (93.3) | 268 (96.1) | 104 (94.5) | 296 (93.7) | |||
| None | 26 (6.1) | 13 (7.5) | 10 (5.8) | 0.649 | 4 (6.7) | 11 (3.9) | 0.538 | 6 (5.5) | 20 (6.3) | 0.399 |
| FOLFOX | 161 (37.8) | 72 (41.6) | 73 (41.7) | 30 (50.0) | 112 (40.1) | 50 (45.5) | 111 (35.1) | |||
| FOLFIRI | 36 (8.5) | 13 (7.5) | 10 (5.7) | 4 (6.7) | 25 (9.0) | 7 (6.4) | 29 (9.2) | |||
| CAPEOX | 177 (41.5) | 60 (34.7) | 72 (41.1) | 20 (33.3) | 119 (42.7) | 41 (37.2) | 136 (43.0) | |||
| Single agent | 26 (6.1) | 15 (8.7) | 10 (5.7) | 2 (3.3) | 12 (4.3) | 6 (5.5) | 20 (6.3) | |||
| None | 26 (6.1) | 13 (7.5) | 10 (5.7) | 0.858 | 2 (6.7) | 11 (3.9) | 0.366 | 6 (5.5) | 20 (6.3) | 0.687 |
| 3 months | 148 (34.7) | 57 (32.9) | 61 (34.9) | 25 (41.7) | 94 (33.7) | 41 (37.3) | 107 (33.9) | |||
| 6 months | 253 (59.2) | 103 (59.5) | 104 (59.4) | 31 (51.7) | 174 (62.4) | 63 (57.3) | 189 (59.8) | |||
| Yes | 50 (11.7) | 22 (12.7) | 19 (10.9) | 0.621 | 21 (35) | 19 (6.8) | 36 (32.7) | 14 (4.4) | ||
| No | 376 (88.3) | 151 (87.3) | 156 (89.1) | 39 (65) | 260 (93.2) | 74 (67.3) | 302 (95.6) | |||
| Locoregional only | 9/50 (12.0) | 3/22 (13.6) | 6/19 (31.4) | 0.260 | 3/21 (14.3) | 4/19 (21.1) | 0.689 | 6/36 (16.7) | 3/14 (21.4) | 0.697 |
| Distant±locoregional | 41/50 (82.0) | 19/22 (86.4) | 13/19 (68.4) | 18/21 (85.7) | 15/19 (78.9) | 30/36 (83.3) | 11/14 (78.6) | |||
| 6–12 months | 101 (23.7) | 49 (28.3) | 49 (28) | 0.158 | 17 (28.3) | 81 (29) | 0.351 | 22 (20) | 79 (25) | 0.677 |
| 12–24 months | 276 (64.8) | 120 (69.4) | 113 (64.6) | 36 (60) | 188 (67.4) | 73 (66.4) | 203 (64.2) | |||
| 24–36 months | 42 (9.9) | 4 (2.3) | 12 (6.9) | 7 (11.7) | 9 (3.2) | 13 (11.8) | 29 (9.2) | |||
| >36 months | 7 (1.6) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.4) | 2 (1.8) | 5 (1.6) | |||
| mSEPT9 – methylated Septin9; ACT – adjuvant chemotherapy. | ||||||||||